Dihydroberberine Beyond Better Absorption: New Research Points to a Glucose-Sensing Mechanism

Berberine has become one of the most talked-about natural compounds for blood sugar and metabolic health. The problem is that standard berberine is not absorbed very well. A person may take a large dose, but only a small amount may actually make it into the bloodstream [1].

Dihydroberberine, often shortened to DHB and the form used in Healthmasters' Berberine Ultimate, was developed to solve that problem. It is a more absorbable form that can pass through the intestinal wall more easily and then convert back into berberine inside the body [1]. Earlier human research found that much smaller amounts of DHB produced higher blood levels of berberine than a much larger dose of standard berberine [1].

That alone makes DHB interesting. But a newer study suggests that DHB may do more than simply improve absorption.

A 2026 study published in Diabetes, Obesity and Metabolism found that DHB may help pancreatic cells release insulin by acting on glucokinase, an enzyme that helps the pancreas sense rising blood sugar [2]. The research was mainly conducted in insulin-producing cells and diabetic mice; still, the study gives researchers a specific mechanism to investigate and helps explain why DHB may have metabolic effects beyond better absorption.

Why Standard Berberine Has an Absorption Problem

Berberine is a plant compound found in herbs such as barberry and goldenseal. Researchers have studied it for possible effects on blood sugar, insulin signaling, cholesterol, inflammation, and cellular energy [1].

Its biggest weakness is poor bioavailability [1]. Bioavailability simply means how much of a substance enters the bloodstream and becomes available for the body to use. The amount printed on a supplement label is not necessarily the amount that reaches the blood.

Standard berberine has difficulty crossing the intestinal wall [1]. Much of it may remain in the digestive tract or be broken down before reaching circulation [1]. That is one reason ordinary berberine products often use large serving sizes.

Large amounts may also be harder on the digestive system. Some users report constipation, diarrhea, cramping, nausea, or general stomach discomfort with conventional berberine.

DHB takes a different approach. Instead of simply adding more standard berberine, it uses a form designed to cross the intestinal barrier more efficiently [1]. After absorption, DHB is converted back into berberine, creating higher circulating berberine exposure from a smaller amount [1].

What the Human Absorption Study Found

In an earlier randomized crossover trial, researchers compared 500 mg of standard berberine with 100 mg and 200 mg of DHB [1]. The participants received each form on separate occasions, and researchers measured blood levels afterward [1].

Both DHB doses produced substantially higher circulating berberine levels than 500 mg of ordinary berberine [1]. Even the 100 mg DHB dose produced greater blood exposure than the much larger standard berberine dose [1].

This is important because supplement doses cannot always be compared milligram for milligram. A smaller amount of a better-absorbed form may deliver more active material into the bloodstream than a larger amount of a poorly absorbed form [1].

The study was small and short-term, but he strongest conclusion from that study is straightforward: DHB appears to deliver berberine into the bloodstream more efficiently than standard berberine [1].

The New Research Asked a Different Question

The 2026 study went beyond absorption. The researchers wanted to know whether DHB could directly affect the insulin-release process [2].

Insulin is made by beta cells in the pancreas. Its job is to help move glucose out of the blood and into cells, where it can be used for energy or stored for later [2].

Beta cells must be able to detect when blood sugar is rising. They should not release large amounts of insulin all the time. They need a sensing system that tells them when glucose is high enough to require a response [2].

The researchers focused on glucokinase because it plays an important role in that sensing system [2].

Glucokinase: The Pancreas’s Blood Sugar Sensor

Glucokinase is an enzyme found mainly in the pancreas and liver [2]. In pancreatic beta cells, it helps detect how much glucose is available [2].

A simple way to understand glucokinase is to think of it as part of the pancreas’s fuel gauge. When glucose enters a beta cell, glucokinase helps begin the process of using that glucose for energy [2]. As the cell processes more glucose, it produces signals that lead to insulin release [2].

When the system works properly, insulin rises in response to higher blood sugar. When beta cells do not sense glucose well, insulin release may become delayed or inadequate [2].

The researchers wanted to know whether DHB could interact with glucokinase and improve this glucose-sensing response [2].

DHB Increased Insulin Release in Cell Models

The researchers tested DHB in two types of insulin-producing cells known as INS-1 and MIN6 cells [2]. These are commonly used laboratory models for studying pancreatic beta-cell behavior [2].

DHB increased glucose-stimulated insulin secretion in both cell types [2]. In other words, when glucose was present, the cells released more insulin after being exposed to DHB [2].

That wording is important. The researchers were not simply looking for uncontrolled insulin release. They were testing whether DHB improved the cells’ response to glucose [2].

A healthy pancreas should release more insulin when blood sugar rises. The study suggests that DHB may strengthen that response, at least in laboratory cells [2].

How the Researchers Connected DHB to Glucokinase

The researchers used several methods to determine whether glucokinase was involved [2].

First, they used molecular docking. This is a computer method that predicts whether one molecule can fit into and interact with another molecule [2]. The results suggested that DHB could bind to glucokinase [2].

Computer predictions alone are not enough, so the researchers performed additional testing [2]. They used a method called a cellular thermal shift assay, which can help show whether a compound physically interacts with a protein inside cells [2]. The results supported a direct interaction between DHB and glucokinase [2].

The researchers then used a technique that reduced the amount of glucokinase produced by the cells [2]. This is sometimes called a knockdown experiment. The purpose is simple: if glucokinase is truly important, reducing it should weaken DHB’s effects.

That is what happened [2]. When glucokinase levels were reduced, DHB caused much less glucose-stimulated insulin release [2]. DHB also became less effective at protecting beta cells from apoptosis, which is a controlled form of cell death [2].

This strengthens the case that glucokinase was not just present in the background. It appeared to be an important part of DHB’s activity [2].

What Happened in the Animal Experiments

The researchers also tested DHB in diabetic mice [2]. They used glucose-tolerance testing to see how well the animals handled a measured dose of glucose [2].

DHB improved glucose tolerance and increased insulin release in the animals [2]. In simpler terms, the treated mice handled the glucose challenge better and produced a stronger insulin response [2].

These results support the cell findings, but they still do not automatically prove the same outcome will occur in humans. Animals process compounds differently, and laboratory diabetes models do not perfectly copy human type 2 diabetes [2].

There are several human clinical trials using DBH, and when those studies are published, Healthmasters will provide an updated article overviewing those findings.

Why Healthmasters’ Berberine Ultimate Uses DHB

Healthmasters’ Berberine Ultimate uses dihydroberberine to address the main weakness of conventional berberine: poor absorption.

Instead of relying on a large amount of ordinary berberine, the formula uses a form that has produced much higher circulating berberine levels from smaller doses in human research [1]. That makes it a more advanced approach for people interested in berberine-based metabolic support.

The newer glucokinase study makes DHB even more relevant. The ingredient did not merely show better absorption. It also increased glucose-responsive insulin release, appeared to bind glucokinase, and became less effective when glucokinase was reduced [2].

Conclusion

Dihydroberberine was originally valued because it appears to solve the absorption problem of standard berberine [1]. The new research suggests it may also interact with glucokinase, an enzyme that helps pancreatic cells sense blood sugar and decide when to release insulin [2].

In laboratory cells, DHB increased glucose-stimulated insulin secretion [2]. In diabetic mice, it improved glucose tolerance and insulin release [2]. When researchers reduced glucokinase, many of DHB’s effects became weaker [2].

These findings are promising, but they are still mainly preclinical. Human trials are needed—and are in the works—to determine whether DHB meaningfully improves A1c, fasting glucose, body weight, appetite, or long-term metabolic health.

Healthmasters’ Berberine Ultimate fits the evidence where it is strongest. It uses a better-absorbed form of berberine and provides access to an ingredient now being studied for a possible direct role in the body’s glucose-sensing machinery.

NOTE: People taking insulin, metformin, sulfonylureas, GLP-1 medications, or other blood-sugar-lowering drugs should speak with a healthcare professional before using DHB, since combining several glucose-lowering approaches may require closer monitoring.

References

[1] Moon, J. M., Ratliff, K. M., Hagele, A. M., Stecker, R. A., Mumford, P. W., Kerksick, C. M., et al. (2022). Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: A randomized, controlled, crossover pilot trial. Nutrients, 14(1), 124. https://doi.org/10.3390/nu14010124

[2] Zhang, C., Zhang, X., Zhang, Q., Zhao, R., Xiong, F., Wei, G., Ke, X., & Lu, J. (2026). Dihydroberberine normalizes insulin secretion by regulating glucokinase. Diabetes, Obesity and Metabolism, 28(1), 151–165. https://doi.org/10.1111/dom.70171

*The matters discussed in this article are for informational purposes only and not medical advice. Please consult your healthcare practitioner on the matters discussed herein.

*These statements have not been evaluated by the Food and Drug Administration. Healthmasters' products are not intended to diagnose, treat, cure, or prevent any disease.